



## Ocugen, Inc. to Present at NobleCon18

April 19, 2022

MALVERN, Pa., April 19, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene therapies, biologicals and vaccines, today announces that Dr. Shankar Musunuri, Chairman, CEO and Co-Founder of Ocugen, will present on-location at NobleCon18 - Noble Capital Markets' Eighteenth Annual Investor Conference.

Event	Noble Capital Markets' Eighteenth Annual Investor Conference
Date	April 21, 2022
Presentation	10:30AM Eastern Time
On-site location	Terrace Ballroom B Hard Rock Hotel & Casino, Hollywood, Florida

A high-definition, video webcast of [the presentation will be available the following day on Ocugen's website](#), and as part of a complete catalog of presentations available at Noble Capital Markets' Conference website: [www.nobleconference.com](http://www.nobleconference.com) and on Channelchek [www.channelchek.com](http://www.channelchek.com) the investor portal created by Noble. The webcast will be archived on the company's website, the NobleCon website and on Channelchek.com for 90 days following the event.

### About Ocugen, Inc.

Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene therapies, biologicals and vaccines that improve health and offer hope for people and global communities. We are making an impact through courageous innovation, taking science in new directions in service of patients. Our breakthrough modifier gene therapy platform has the potential to treat multiple diseases with one drug and we are advancing research in other therapeutic areas to offer new options for people with unmet medical needs. Discover more at [www.ocugen.com](http://www.ocugen.com) and follow us on [Twitter](#) and [LinkedIn](#).

### About Noble

Noble Capital Markets ("Noble") is a research driven investment bank that has supported small & microcap companies since 1984. As a FINRA and SEC licensed broker dealer Noble provides institutional-quality equity research, merchant and investment banking, and order execution services. In 2005, Noble established NobleCon, an investor conference that has grown substantially over the last decade. Noble launched [www.channelchek.com](http://www.channelchek.com) in 2018 - an investor community dedicated exclusively to public small and micro-cap companies and their industries. Channelchek is the first service to offer institutional-quality research to the public, for FREE at every level without a subscription. More than 6,000 public emerging growth companies are listed on the site, with growing content including research, webcasts, podcasts, and balanced news.

### Cautionary Note on Forward-Looking Statements

*This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from our current expectations. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission ("SEC"), including the risk factors described in the section entitled "Risk Factors" in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events or otherwise, after the date of this press release.*

### Ocugen Contact:

Ken Inchausti  
Head, Investor Relations & Communications  
[ken.inchausti@ocugen.com](mailto:ken.inchausti@ocugen.com)

For investor-related inquiries: [IR@Ocugen.com](mailto:IR@Ocugen.com)